PL359624A1 - Clear aqueous anaesthetic composition - Google Patents

Clear aqueous anaesthetic composition

Info

Publication number
PL359624A1
PL359624A1 PL00359624A PL35962400A PL359624A1 PL 359624 A1 PL359624 A1 PL 359624A1 PL 00359624 A PL00359624 A PL 00359624A PL 35962400 A PL35962400 A PL 35962400A PL 359624 A1 PL359624 A1 PL 359624A1
Authority
PL
Poland
Prior art keywords
clear aqueous
propofol
compositions
composition
hydroxypropyl
Prior art date
Application number
PL00359624A
Other languages
English (en)
Polish (pl)
Inventor
Srikanth Pai
Sangeeta Rivankar
Shilpa Kocharekar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of PL359624A1 publication Critical patent/PL359624A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00359624A 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition PL359624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (OSRAM) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (1)

Publication Number Publication Date
PL359624A1 true PL359624A1 (en) 2004-08-23

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00359624A PL359624A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Country Status (26)

Country Link
US (1) US7138387B2 (OSRAM)
EP (1) EP1299095B1 (OSRAM)
JP (1) JP4907833B2 (OSRAM)
KR (1) KR100810066B1 (OSRAM)
CN (1) CN1254237C (OSRAM)
AP (1) AP2002002674A0 (OSRAM)
AT (1) ATE267592T1 (OSRAM)
AU (2) AU2001235972B2 (OSRAM)
BG (1) BG107463A (OSRAM)
BR (1) BR0017268A (OSRAM)
CA (1) CA2414064C (OSRAM)
DE (1) DE60011149T2 (OSRAM)
DK (1) DK1299095T3 (OSRAM)
EA (1) EA005589B1 (OSRAM)
ES (1) ES2222271T3 (OSRAM)
HU (1) HUP0301646A3 (OSRAM)
IL (1) IL153387A0 (OSRAM)
IN (1) IN187686B (OSRAM)
MX (1) MXPA02012611A (OSRAM)
NO (1) NO20025999L (OSRAM)
NZ (1) NZ523643A (OSRAM)
PL (1) PL359624A1 (OSRAM)
PT (1) PT1299095E (OSRAM)
WO (1) WO2001097796A1 (OSRAM)
YU (1) YU2703A (OSRAM)
ZA (1) ZA200300336B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (OSRAM) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2005517679A (ja) * 2001-12-28 2005-06-16 ギルフォード ファーマシューティカルズ インコーポレイテッド プロポフォールの水溶性プロドラッグの水ベースの薬学的製剤
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
MXPA05001061A (es) * 2002-07-29 2005-10-05 Transform Pharmaceuticals Inc Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
ES2685436T3 (es) * 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
KR20060130646A (ko) * 2004-01-14 2006-12-19 가부시키가이샤 오츠까 세이야꾸 고죠 프로포폴 함유 지방 유제
BRPI0515181A (pt) * 2004-09-13 2008-07-22 Bharat Serums & Vaccines Ltd composição de óleo-em-água estéril para administração intravenosa, uso de um monoglicerìdeo e processo de preparação de uma composição para administração intravenosa
AU2006310044A1 (en) * 2005-08-12 2007-05-10 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8663874B2 (en) * 2008-03-11 2014-03-04 3M Innovative Properties Company Hardcoat composition
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US9096712B2 (en) 2009-07-21 2015-08-04 3M Innovative Properties Company Curable compositions, method of coating a phototool, and coated phototool
EP2478034A1 (en) 2009-09-16 2012-07-25 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8748060B2 (en) 2009-09-16 2014-06-10 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
JP5819005B2 (ja) 2011-11-29 2015-11-18 ジュロックス プロプライエタリー リミテッド 薬学的組成物
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
SG10201608148TA (en) 2012-08-21 2016-11-29 Sage Therapeutics Inc Methods Of Treating Epilepsy Or Status Epilepticus
WO2017132243A1 (en) * 2016-01-29 2017-08-03 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
US7138387B2 (en) 2006-11-21
NZ523643A (en) 2004-05-28
EA005589B1 (ru) 2005-04-28
AU2001235972B2 (en) 2005-07-21
ES2222271T3 (es) 2005-02-01
WO2001097796A1 (en) 2001-12-27
AU3597201A (en) 2002-01-02
DE60011149D1 (de) 2004-07-01
KR100810066B1 (ko) 2008-03-05
CA2414064A1 (en) 2001-12-27
EP1299095A1 (en) 2003-04-09
CN1454085A (zh) 2003-11-05
DK1299095T3 (da) 2004-10-11
MXPA02012611A (es) 2004-07-30
US20040014718A1 (en) 2004-01-22
PT1299095E (pt) 2004-10-29
HUP0301646A3 (en) 2005-06-28
HUP0301646A2 (hu) 2003-09-29
CA2414064C (en) 2013-01-08
JP2003535893A (ja) 2003-12-02
DE60011149T2 (de) 2005-07-07
BR0017268A (pt) 2003-05-27
IL153387A0 (en) 2003-07-06
ZA200300336B (en) 2004-04-08
KR20030023875A (ko) 2003-03-20
IN187686B (OSRAM) 2002-06-08
NO20025999D0 (no) 2002-12-13
EP1299095B1 (en) 2004-05-26
NO20025999L (no) 2002-12-13
ATE267592T1 (de) 2004-06-15
AP2002002674A0 (en) 2002-12-31
CN1254237C (zh) 2006-05-03
YU2703A (sh) 2006-03-03
BG107463A (en) 2003-11-28
EA200300047A1 (ru) 2003-06-26
JP4907833B2 (ja) 2012-04-04

Similar Documents

Publication Publication Date Title
PL359624A1 (en) Clear aqueous anaesthetic composition
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
DK1157037T3 (da) GCSF-konjugater
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
SE0001899D0 (sv) New compounds
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ES2171462T3 (es) Ciclodextranos para la reduccion de la extravasacion causada por compuestos citotoxicos.
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
MX228228B (es) Composiciones de propofol claras, estables.
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
BR0109617A (pt) Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0212915A (pt) Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs
IL147901A0 (en) Phenanthroline-7-one derivatives and their therapeutic uses
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
AR038017A1 (es) Composicion anestesica acuosa y clara
BR0316968A (pt) Composições estáveis, claras, aquosas de ifosfamida para administração parenteral que apresentam pouca toxicidade; processo para a preparação de composições de ifosfamida; e composições de ifosfamida e um processo para a preparação das mesmas